Opus Genetics, Inc. (IRD)

Compare

0.8861

-0.0938

(-9.57%)

At close: April 4 at 4:00:02 PM EDT

0.9200

+0.03

+(3.83%)

After hours: April 4 at 7:18:03 PM EDT

Party Time: Brokers Just Made Major Increases To Their Opus Genetics, Inc. (NASDAQ:IRD) Earnings Forecasts

Celebrations may be in order for Opus Genetics, Inc. ( NASDAQ:IRD ) shareholders, with the analysts delivering a...

Simply Wall St. yesterday

IRD
-9.57%
Opus Genetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Opus Genetics ( NASDAQ:IRD ) Full Year 2024 Results Key Financial Results Revenue: US$11.0m (down 42% from FY 2023...

Simply Wall St. 2 days ago

IRD
-9.57%
Opus Genetics to Participate in Upcoming Investor Conference in April

RESEARCH TRIANGLE PARK, N.C., April 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and therapies for other ophthalmic disorders, today announced that George Magrath, M.D., Chief Executive Officer, will participate in the following upcoming investor conference in April. Event:RBC Capital Markets Ophthalmology ConferenceLocation:VirtualPresenter:Dr. Ge

GlobeNewswire 4 days ago

IRD
-9.57%
Opus Genetics Announces Financial Results for Full Year 2024

Provides update on the Company’s transformation and promising portfolio of innovative gene therapy treatments for inherited retinal diseases Strong cash position with $21.5 million financing to supplement $30.3 million year-end balance New capital supports delivery on key milestones for two lead gene therapy candidates OPGx-LCA5 and OPGx-BEST1 RESEARCH TRIANGLE PARK, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (“Opus” or the “Company”) (Nasdaq: IRD), a clinical-stage ophthalmic

GlobeNewswire 6 days ago

IRD
-9.57%
Several Insiders Invested In Opus Genetics Flagging Positive News

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...

Simply Wall St. 11 days ago

IRD
-9.57%
Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Believes that Current Board’s Strategic, Management and Capital Allocation Failures have Resulted in Stockholder Value Destruction Highlights Serious Concerns with the Opus Merger and the Company’s Underperformance Preliminary Proxy Materials Present an Alternative Strategy to Create Significant Stockholder Value Without Extreme Dilution Today’s Dilutive Financing Showcases the Board’s Willingness to Unreasonably Tilt the Playing Field and Undermines the Vote Ahead of Pivotal Election WEST BLOOM

GlobeNewswire 16 days ago

IRD
-9.57%
Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

RESEARCH TRIANGLE PARK, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and therapies for other ophthalmic disorders, today announced that a presentation featuring the LYNX-1 Phase 3 study of Phentolamine Ophthalmic Solution 0.75% in patients with dim light disturbances will be delivered this week at World Cornea Congress IX, taking place

GlobeNewswire 16 days ago

IRD
-9.57%
Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million

Additional approximately $21 million tied to data release for the Company’s BEST1 programRESEARCH TRIANGLE PARK, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (“Opus” or the “Company”) (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and therapies for other ophthalmic disorders, today announced the pricing of an underwritten public offering with gross proceeds of $20 million and concur

GlobeNewswire 16 days ago

IRD
-9.57%
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., March 19, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing important new therapies for the treatment of inherited retinal diseases (IRDs) and other ophthalmic disorders (“Opus” or the “Company”), today announced that the independent members of its Board of Directors approved equity awards under the Company’s 2021 Inducement Plan, as amended, as a material inducement to two new employees in c

GlobeNewswire 18 days ago

IRD
-9.57%
Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

New Data from First Three Adult Patients in Phase 1/2 Trial with OPGx-LCA5 Showed that Subjective and Objective Signs of Efficacy Persisted for One YearDurham, NC., March 05, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other ophthalmologic disorders, today announced that three abstracts on its investigational gene therapy candidates have been acce

GlobeNewswire last month

IRD
-9.57%
Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

FDA Fast Track Designation granted for Phentolamine Ophthalmic Solution 0.75% as treatment of significant chronic night driving impairment in keratorefractive patients with reduced mesopic vision Enrollment completion in LYNX-2 pivotal Phase 3 trial expected in first half of 2025 Enrollment now complete in VEGA-3 pivotal Phase 3 trial evaluating Phentolamine Ophthalmic Solution 0.75% for presbyopia DURHAM, N.C., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stag

GlobeNewswire last month

IRD
-9.57%
Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 2025New 12-month data on the first three adult OPGx-LCA5 patients to be presented at a major medical conference in Q2 2025FDA meeting scheduled in March 2025 to discuss Phase 3 trial design and registrational endpoints for OPGx-LCA5 DURHAM, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developi

GlobeNewswire last month

IRD
-9.57%
Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

Current Board’s Strategic, Management, and Capital Allocation Failures Have Driven an 80% Stock Decline Over Last 22 Months New Leadership is Urgently Needed to Restore Accountability in the Boardroom Restore Value Slate Brings Deep Industry Expertise, Operational Discipline, and Strong Shareholder Alignment MICHIGAN, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mina Sooch, founder of Ocuphire Pharma, Inc., now known as Opus Genetics, Inc. (NASDAQ: IRD) (“Opus” or the “Company”), today announced that she h

GlobeNewswire last month

IRD
-9.57%
Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

Agreement Reached on Primary Endpoint and Phase 3 Trial Design Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering FARMINGTON HILLS, Mich., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small-molecule drugs to treat other ophthalmologic disorders, today announced that it has reached agreement with the U.S. Food and Drug Adm

GlobeNewswire 3 months ago

IRD
-9.57%
Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024

6-month efficacy and safety data from ongoing Phase 1/2 trial of OPGx-LCA5 to be presentedFARMINGTON HILLS, Mich., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other ophthalmic disorders, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, December 11, 2024 at 4:00 PM ET. To register, click here. The ev

GlobeNewswire 4 months ago

IRD
-9.57%
Opus Genetics reinstated with a Buy at H.C. Wainwright

H.C. Wainwright reinstated coverage of Opus Genetics (IRD) with a Buy rating and $8 price target The firm believes inherited retinal disease development presents an efficient path to concise studies offering insight into gene therapy efficacy. The firm believes the company’s 2025 catalysts can give the its platform the appropriate foundation for continued innovation and development over the near-term. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial

TipRanks 4 months ago

IRD
-9.57%
The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics

The RD Fund (Retinal Degeneration Fund) – the venture arm of the Foundation Fighting Blindness – announces the all-stock acquisition of Opus Genetics, Inc. "Opus" (private) by Ocuphire Pharma, Inc., (Nasdaq: OCUP) a clinical-stage ophthalmic biopharmaceutical company. The companies have combined under the name of Opus Genetics to create a transformative biotech company committed to being a leader in the development of gene therapies for the treatment of inherited retinal diseases (IRDs). The com

PR Newswire 5 months ago

IRD
-9.57%
OCUP

Performance Overview

Return	IRD	S&P 500 (^GSPC)
YTD	-25.54%	-13.73%
1-Year	-52.87%	-1.42%
3-Year	-72.74%	+10.72%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Opus Genetics, Inc. (IRD)

Party Time: Brokers Just Made Major Increases To Their Opus Genetics, Inc. (NASDAQ:IRD) Earnings Forecasts

Opus Genetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Opus Genetics to Participate in Upcoming Investor Conference in April

Opus Genetics Announces Financial Results for Full Year 2024

Several Insiders Invested In Opus Genetics Flagging Positive News

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024

Opus Genetics reinstated with a Buy at H.C. Wainwright

The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics

Performance Overview